TW202317118A - 含有二氫嗒-3,5-二酮衍生物的製劑 - Google Patents
含有二氫嗒-3,5-二酮衍生物的製劑 Download PDFInfo
- Publication number
- TW202317118A TW202317118A TW111121208A TW111121208A TW202317118A TW 202317118 A TW202317118 A TW 202317118A TW 111121208 A TW111121208 A TW 111121208A TW 111121208 A TW111121208 A TW 111121208A TW 202317118 A TW202317118 A TW 202317118A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- weight
- formula
- less
- compound represented
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-096206 | 2021-06-08 | ||
| JP2021096206 | 2021-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202317118A true TW202317118A (zh) | 2023-05-01 |
Family
ID=84426023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111121208A TW202317118A (zh) | 2021-06-08 | 2022-06-08 | 含有二氫嗒-3,5-二酮衍生物的製劑 |
Country Status (12)
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012012421A (es) | 2010-04-28 | 2012-12-17 | Astellas Pharma Inc | Compuestos tetrahidrobenzotiofena. |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| PL2772490T3 (pl) | 2011-10-27 | 2016-11-30 | Aminoalkilo-podstawiona pochodna n-tienylobenzamidu | |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| AU2014230552B2 (en) * | 2013-03-13 | 2017-11-16 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative |
| US9499553B2 (en) * | 2013-03-13 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same |
| SMT202100481T1 (it) | 2014-08-18 | 2021-09-14 | Alkermes Pharma Ireland Ltd | Composizioni per profarmaci di aripiprazolo |
| EP4374877A3 (en) | 2014-09-12 | 2024-07-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification. |
| MX376202B (es) | 2016-08-15 | 2025-03-07 | Lilly Co Eli | Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. |
| WO2019060604A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE MEDICINE |
| US12097204B2 (en) * | 2018-09-03 | 2024-09-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof |
-
2022
- 2022-06-08 WO PCT/JP2022/023076 patent/WO2022260064A1/ja not_active Ceased
- 2022-06-08 KR KR1020237045200A patent/KR20240018523A/ko active Pending
- 2022-06-08 US US18/567,435 patent/US20240293402A1/en active Pending
- 2022-06-08 AU AU2022288895A patent/AU2022288895A1/en active Pending
- 2022-06-08 CA CA3221186A patent/CA3221186A1/en active Pending
- 2022-06-08 IL IL309056A patent/IL309056A/en unknown
- 2022-06-08 EP EP22820243.8A patent/EP4353233A4/en active Pending
- 2022-06-08 MX MX2023014507A patent/MX2023014507A/es unknown
- 2022-06-08 CN CN202280041019.3A patent/CN117460511A/zh active Pending
- 2022-06-08 TW TW111121208A patent/TW202317118A/zh unknown
- 2022-06-08 JP JP2023527886A patent/JPWO2022260064A1/ja active Pending
- 2022-06-08 BR BR112023023708A patent/BR112023023708A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240018523A (ko) | 2024-02-13 |
| CN117460511A (zh) | 2024-01-26 |
| MX2023014507A (es) | 2024-01-26 |
| EP4353233A1 (en) | 2024-04-17 |
| BR112023023708A2 (pt) | 2024-01-30 |
| AU2022288895A1 (en) | 2024-01-18 |
| US20240293402A1 (en) | 2024-09-05 |
| IL309056A (en) | 2024-02-01 |
| WO2022260064A1 (ja) | 2022-12-15 |
| JPWO2022260064A1 (cg-RX-API-DMAC7.html) | 2022-12-15 |
| EP4353233A4 (en) | 2025-06-25 |
| CA3221186A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI325318B (en) | Capsule and method of manufacturing the same | |
| BG64691B1 (bg) | Зипрасидонови препарати | |
| SA517390473B1 (ar) | أشكال جرعة صلبة من بالبوسيكليب | |
| EP2627319B1 (en) | Pharmaceutical compositions containing a dgat1 inhibitor | |
| TW201531309A (zh) | N-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕苯甲醯胺之藥學組成物 | |
| HK1213814A1 (zh) | 双氯芬酸制剂和使用方法 | |
| TW201216962A (en) | Formulation for solubility enhancement of poorly soluble drugs | |
| JP2009542647A (ja) | メマンチン医薬組成物 | |
| JP4805234B2 (ja) | 経口固形医薬 | |
| EP3290037A1 (en) | Pharmaceutical composition for oral administration | |
| EP2514422B1 (en) | Elution stabilized teneligliptin preparation | |
| JP2023531606A (ja) | アカラブルチニブマレイン酸塩剤形 | |
| WO2021216545A1 (en) | Oral solid meloxicam formulations for the treatment of acute pain | |
| WO2022260064A1 (ja) | ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤 | |
| HK40104119A (en) | Formulation containing dihydropyridazine-3,5-dione derivative | |
| US20240100088A1 (en) | Novel formulation for treating copper metabolism-associated diseases or disorders | |
| JP7109255B2 (ja) | 粉砕物の製造方法及び錠剤の製造方法 | |
| EP3162368A1 (en) | Pharmaceutical composition for oral administration | |
| EP4059504A1 (en) | Drug substance of lemborexant and medicinal composition comprising same | |
| WO2023085300A1 (ja) | 優れた溶出性を有する医薬組成物 | |
| Munnangi | Advancing Pharmaceutical Manufacturing: Innovative Applications of Hot Melt Extrusion for the Preparation of Drug Complexes and Fixed Dose Combination Immediate Release Formulation with Diverse Crystalline Properties | |
| EP4721739A1 (en) | Csf-1r inhibitor pharmaceutical composition, preparation method therefor and pharmaceutical use thereof | |
| JP2011073972A (ja) | 混合粉体およびその製造方法、固形製剤 | |
| CN107137374A (zh) | 帕洛诺司琼的固体药物组合物 | |
| LUST | ANDRES LUST |